XML 61 R45.htm IDEA: XBRL DOCUMENT

Expenses (Tables)

12 Months Ended

Jun. 30, 2023

Text block [abstract]

Summary of expenses


		2023 A$’000				2022 restated A$’000				2021 restated A$’000



Loss before income tax includes the following specific

Research and development
EVT-801 program costs			5,060				2,520				1,073
Cantrixil program costs			5				12				429
Paxalisib program costs			5,618				13,713				11,404
Scientific Advisory Board costs			31				—				—
Employee benefits expense - salaries & wages and staff benefits			2,250				1,665				336
- superannuation			29				25				26
- share based payments			702				365				8
Total research & development (excluding amortisation)			13,695				18,300				13,276

Amortisation
Paxalisib licensing agreement			1,084				1,084				1,084
Evotech licensing agreement			785				785				181

Total amortisation			1,869				1,869				1,265

Total research & development			15,564				20,169				14,541

Net foreign exchange loss
Net foreign exchange loss			46				(2,154	)			409

Rental expense relating to operating leases
Minimum lease payments			152				73				93

Superannuation expense
Defined contribution superannuation expense			131				138				138

Employee benefits expense G&A
- salaries & wages and staff benefits			1,467				1,674				1,011
- superannuation			102				129				112
- share based payments			457				1,310				552

Total employee benefits expense G&A			2,026				3,113				1,675


Other Expenses
Chinese With-Holding Tax incurred on license transaction			—				—				931
Chinese Value Added Tax incurred on license transaction			—				—				538

			—				—				1,469